Vanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review HETLIOZ™ NDA

WASHINGTON, Nov. 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that NASDAQ halted trading of Vanda common stock this morning.  

The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review Vanda's New Drug Application (NDA) for tasimelteon, proposed trade name HETLIOZ, for the treatment of Non-24-Hour Disorder in the totally blind.  The Advisory Committee meeting is scheduled for 8:00 am ET

Vanda's HETLIOZ NDA is currently under Priority Review by the FDA with an action target date under the Prescription Drug User Fee Act (PDUFA-V) of January 31, 2014.  

Investor Contact:
Chad Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@troutgroup.com

Media Contact:
Laney Landsman
Assistant Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com

SOURCE Vanda Pharmaceuticals Inc.



RELATED LINKS
http://www.vandapharma.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.